All News

Global Ophthalmic Suspension Market Is Projected To Grow Massively In Near Future With Profiling Eminent Players-Genentech, Inc. (US), Falcon Group (India), Cirondrugs (India), Dolvis Bio Pharma Private Limited (India), Parenteral Drug Association

Global Ophthalmic Suspension Market accounted to significant growth at a CAGR of 6.8% during the forecast period of 2019 to 2026. The upcoming market report contains data for historic years 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

 Ophthalmic Suspension market research report has been delivered by including exceptionally created understanding and examination which outfits greatest advantages to the healthcare  business. The market investigation did in this report underlines different sections that are depended upon to observe the speediest advancement dependent on the assessed estimate outline. This market report utilizes most present day devices and strategies for gathering, investigating, breaking down and assessing market information. The valid Ophthalmic Suspension report brings into light key industry patterns, market size, piece of the pie appraisals, and deals volume that help healthcare  industry to hypothesize the systems to upgrade rate of profitability (ROI).

Few of the major competitors currently working in global ophthalmic suspension market are Novartis AG (Switzerland), ALLERGAN (Ireland)plc, Pfizer Inc. (US), Merck Co. & Inc. (US), Bausch Health Companies Inc. (Canada), Bayer AG (Germany), Genentech, Inc. (US), Falcon Group (India), Cirondrugs (India), Dolvis Bio Pharma Private Limited (India), Parenteral Drug Association, Jubilant Life Sciences Ltd. (India), ENTOD INTERNATIONAL (India), Akums (India), UBM (UK), FDC (India) and Dev Life Corporation (India) among others.

Key Developments in the Market:

  • In August 2018, Sun Pharmaceutical Industries Ltd. announced that it has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the U.S. Food and Drug Administration (FDA) to launching of new drug in market will attract potential customers.
  • On 15th April, 2019, the global leader in ophthalmology, Novartis came up with the innovation by changing the dosage form, has announced FDA filing acceptance and priority review of Brolucizumab (RTH258) for patients with wet AMD. Soon, it will launch in the market and capture the market shares of global ophthalmic suspension market.
  • In March 2019, Rocklatan, a combination drug of Latanoprost and Netarsudil launched in the market for the indication of open-angle glaucoma or ocular hypertension. It can be proved as a blockbuster drug and increase the competition in the market.

Market Drivers:

  • Rise in prevalence rate of eye diseases is one of the major factors contributing to the growth of this market.
  • Increasing geriatric population and growing number of bacterial infections cases in children will also be responsible for the growth of the market.

Market Restraints:

  • Adverse effects in ophthalmic suspension hamper the market.
  • Loss of patent of blockbuster drugs will provide opportunities to penetrate in the market.

To know more about the study @

Segmentation: Global Ophthalmic Suspension Market 

By Type of Content

  • Antibiotic
  • Antifungal
  • Antibacterial
  • Steroids
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

By Treatment Type

  • Bacterial Infections
  • Conjunctivitis
  • Scleritis
  • Retinal disorder
  • Macular Degeneration
  • Branch Retinal Vein Occlusion
  • Central Retinal Vein Occlusion
  • Congenital X-Linked Retinoschisis
  • Glaucoma
  • Allergies
  • Diabetic Eye Disease

By End-User

  • Hospitals
  • Eye Clinics

By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Inquiry For Customize Report With Discount at

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]